Study to Evaluate Efficacy and Tolerability of Micardis®/Micardis® Plus in Patients With Hypertension

Completed

• Conditions: Hypertension
• Interventions: Drug: Micardis®; Drug: Micardis® Plus

• Registration Number: NCT02242357
• Lead Sponsor: Boehringer Ingelheim

Brief Summary

Study to evaluate efficacy and tolerability of Micardis®/Micardis® Plus under usual daily-practice prescribing conditions in hypertensive patients

Detailed Description

Not available

Study Timeline

• Study Start: 2003-01
• Primary Completion: 2003-07
• Status Verified: 2014-09
• Study First Submitted: 2014-09-16
• Study First Submitted QC: 2014-09-16
• Last Update Submitted: 2014-09-16
• Study First Posted: 2014-09-17
• Last Update Posted: 2014-09-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 14553

Inclusion Criteria

• Males and females for whom a medical antihypertensive therapy is indicated
• Age >= 18 years

Read More

Exclusion Criteria

• Age < 18 years

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Patients with hypertension	Micardis®	-
Patients with hypertension	Micardis® Plus	-

Primary Outcome Measures

Name	Time	Method
Change in morning blood pressure (office and self-measured)	up to 6 weeks

Secondary Outcome Measures

Name	Time	Method
Assessment of tolerability by investigator on 5-point scale	at week 6
Change in rate of morning complaints	up to 6 weeks
Assessment of efficacy by investigator on a 5-point scale	at week 6
Number of patients with adverse drug reactions	up to 6 weeks
Change in heart rate	up to 6 weeks